Brief: Poseida Therapeutics Announces Research Collaboration With Takeda For Novel Non-Viral In Vivo Gene Therapies

Poseida Therapeutics

12/10/2021 12:19

Oct 12 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH
TAKEDA FOR NOVEL NON-VIRAL IN VIVO GENE THERAPIES
    * POSEIDA THERAPEUTICS - PARTIES TO COLLABORATE TO INITIALLY
DEVELOP UP TO SIX IN VIVO GENE THERAPY PROGRAMS UTILIZING CO'S
NOVEL TECHNOLOGY PLATFORMS
    * POSEIDA THERAPEUTICS INC - TAKEDA ALSO HAS AN OPTION TO
ADD TWO
ADDITIONAL PROGRAMS TO COLLABORATION
    * POSEIDA THERAPEUTICS INC - TAKEDA IS OBLIGATED TO PROVIDE
FUNDING FOR ALL COLLABORATION PROGRAM RESEARCH AND DEVELOPMENT
COSTS
    * POSEIDA THERAPEUTICS INC - WILL RECEIVE AN UPFRONT PAYMENT
OF
$45 MILLION
    * POSEIDA THERAPEUTICS - WILL RECEIVE PRECLINICAL MILESTONES
THAT
TOGETHER COULD POTENTIALLY EXCEED $125 MILLION, IF MILESTONES
FOR 6 PROGRAMS ARE ACHIEVED
    * POSEIDA - ELIGIBLE TO GET FUTURE MILESTONE PAYMENTS WITH
POTENTIAL VALUE OF UP TO $2.7 BILLION IF MILESTONES FOR 6
PROGRAMS ARE ACHIEVED
    * POSEIDA THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO $3.6
BILLION IF MILESTONES RELATED TO TWO OPTIONAL PROGRAMS ARE ALSO
ACHIEVED

Source text for Eikon:  ID:nPn8xSpB2a 
Further company coverage:  PSTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))